References
1. Daly AS, Xenocostas A, Lipton JH.
Transplantation-associated thrombotic microangiopathy: twenty-two years
later. Bone Marrow Transplant. 2002;30(11):709-15.
2. Dvorak CC, Higham C, Shimano KA.
Transplant-associated thrombotic microangiopathy in pediatric
hematopoietic cell transplant recipients: a practical approach to
diagnosis and management. Front Pediatr. 2019 Apr 9;7:133.
3. Jodele S, Dandoy CE, Myers KC,
El-Bietar J, Nelson A, Wallace G, et al. New approaches in the
diagnosis, pathophysiology, and treatment of pediatric hematopoietic
stem cell transplantation-associated thrombotic microangiopathy.
Transfus Apher Sci. 2016 Apr;54(2):181-90.
4. Moiseev IS, Tsvetkova T, Aljurf M,
Alnounou RM, Bogardt J, Chalandon Y, et al. Clinical and morphological
practices in the diagnosis of transplant-associated microangiopathy: a
study on behalf of Transplant Complications Working Party of the EBMT.
Bone Marrow Transplant. 2019 Jul;54(7):1022-1028.
5. Gavriilaki E, Sakellari I, Batsis
I, Mallouri D, Bousiou Z, Vardi A, et al. Transplantāassociated
thrombotic microangiopathy: Incidence, prognostic factors, morbidity,
and mortality in allogeneic hematopoietic cell transplantation. Clin
Transplant. 2018 Sep;32(9):e13371.
6. Batts ED, Lazarus HM. Diagnosis and
treatment of transplantation-associated thrombotic microangiopathy: real
progress or are we still waiting? Bone Marrow Transplant. 2007
Oct;40(8):709-19.
7. Ho VT, Cutler C, Carter S, Martin
P, Adams R, Horowitz M, et al. Blood and marrow transplant clinical
trials network toxicity committee consensus summary: thrombotic
microangiopathy after hematopoietic stem cell transplantation. Biol
Blood Marrow Transplant. 2005 Aug;11(8):571-5.
8. Pettitt AR, Clark RE. Thrombotic
microangiopathy following bone marrow transplantation. Bone Marrow
Transplant. 1994 Oct;14(4):495-504.
9. Fuge R, Bird JM, Fraser A, Hart D,
Hunt L, Cornish JM, et al. The clinical features, risk factors and
outcome of thrombotic thrombocytopenic purpura occurring after bone
marrow transplantation. Br J Haematol. 2001 Apr;113(1):58-64.
10. Jodele S, Laskin BL, Dandoy CE,
Myers KC, El-Bietar J, Davies SM, et al. A new paradigm: Diagnosis and
management of HSCT-associated thrombotic microangiopathy as multi-system
endothelial injury. Blood Rev. 2015 May;29(3):191-204.
11. Laskin BL, Goebel J, Davies SM,
Jodele S. Small vessels, big trouble in the kidneys and beyond:
hematopoietic stem cell transplantation-associated thrombotic
microangiopathy. Blood. 2011 Aug 11;118(6):1452-62.
12. Arai Y, Yamashita K, Mizugishi K,
Watanabe T, Sakamoto S, Kitano T, et al. Serum neutrophil extracellular
trap levels predict thrombotic microangiopathy after allogeneic stem
cell transplantation. Biol Blood Marrow Transplant. 2013
Dec;19(12):1683-9.
13. Nakamae H, Yamane T, Hasegawa T,
Nakamae M, Terada Y, Hagihara K, et al. Risk factor analysis for
thrombotic microangiopathy after reduced-intensity or myeloablative
allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2006
Jul;81(7):525-31.
14. Hale GA, Bowman LC, Rochester RJ,
Benaim E, Heslop HE, Krance RA, et al. Hemolytic uremic syndrome after
bone marrow transplantation: clinical characteristics and outcome in
children. Biol Blood Marrow Transplant. 2005 Nov;11(11):912-20.
15. Worel N, Greinix HT, Leitner G,
Mitterbauer M, Rabitsch W, Rosenmayr A, et al. ABO-incompatible
allogeneic hematopoietic stem cell transplantation following
reduced-intensity conditioning: close association with
transplant-associated microangiopathy. Transfus Apher Sci. 2007
Jun;36(3):297-304.
16. Willems E, Baron F, Seidel L,
Frere P, Fillet G, Beguin Y. Comparison of thrombotic microangiopathy
after allogeneic hematopoietic cell transplantation with high-dose or
nonmyeloablative conditioning. Bone Marrow Transplant. 2010
Apr;45(4):689-93.
17. Uderzo C, Bonanomi S, Busca A,
Renoldi M, Ferrari P, Iacobelli M, et al. Risk factors and severe
outcome in thrombotic microangiopathy after allogeneic hematopoietic
stem cell transplantation. Transplantation. 2006 Sep 15;82(5):638-44.
18. Shayani S, Palmer J, Stiller T,
Liu X, Thomas SH, Khuu T, et al. Thrombotic microangiopathy associated
with sirolimus level after allogeneic hematopoietic cell transplantation
with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis.
Biol Blood Marrow Transplant. 2013 Feb;19(2):298-304.
19. George JN, Li X, McMinn JR,
Terrell DR, Vesely SK, Selby GB. Thrombotic thrombocytopenic
purpura-hemolytic uremic syndrome following allogeneic HPC
transplantation: a diagnostic dilemma. Transfusion. 2004
Feb;44(2):294-304.
20. Schoettler M, Lehmann LE,
Margossian S, Lee M, Kean LS, Kao PC, et al. Risk factors for
transplant-associated thrombotic microangiopathy and mortality in a
pediatric cohort. Blood Adv. 2020 Jun 9;4(11):2536-47.
21. Choi CM, Schmaier AH, Snell MR,
Lazarus HM. Thrombotic microangiopathy in haematopoietic stem cell
transplantation: diagnosis and treatment. Drugs. 2009;69(2):183-98.
22. Elfeky R, Lucchini G, Lum SH,
Ottaviano G, Builes N, Nademi Z, et al. New insights into risk factors
for transplant-associated thrombotic microangiopathy in pediatric HSCT.
Blood Adv. 2020 Jun 9;4(11):2418-29.
23. Laskin BL, Nehus E, Goebel J,
Furth S, Davies SM, Jodele SJBoB, et al. Estimated versus measured
glomerular filtration rate in children before hematopoietic cell
transplantation. Biol Blood Marrow
Transplant. 2014 Dec;20(12):2056-61.
24. Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC,
et al. Complement blockade for TA-TMA: lessons learned from a large
pediatric cohort treated with eculizumab. Blood. 2020 Mar
26;135(13):1049-1057.
25. Khosla J, Yeh A, Spitzer T, Dey
BR. Hematopoietic stem cell transplant-associated thrombotic
microangiopathy: current paradigm and novel therapies. Bone Marrow
Transplant. 2018 Feb;53(2):129-137.
26. Martinez MT, Bucher C, Stussi G,
Heim D, Buser A, Tsakiris DA, et al. Transplant-associated
microangiopathy (TAM) in recipients of allogeneic hematopoietic stem
cell transplants. Bone Marrow Transplant. 2005 Dec;36(11):993-1000.
27. Changsirikulchai S, Myerson D,
Guthrie KA, McDonald GB, Alpers CE, Hingorani SR. Renal thrombotic
microangiopathy after hematopoietic cell transplant: role of GVHD in
pathogenesis. Clin J Am Soc Nephrol. 2009 Feb;4(2):345-53.
28. Jodele S, Zhang K, Zou F, Laskin
B, Dandoy CE, Myers KC, et al. The genetic fingerprint of susceptibility
for transplant-associated thrombotic microangiopathy. Blood. 2016 Feb
25;127(8):989-96.
29. Labrador J, Lopez-Corral L,
Lopez-Godino O, Vazquez L, Cabrero-Calvo M, Perez-Lopez R, et al. Risk
factors for thrombotic microangiopathy in allogeneic hematopoietic stem
cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or
sirolimus. Bone Marrow Transplant. 2014 May;49(5):684-90.
30. Jodele S, Hirsch R, Laskin B,
Davies S, Witte D, Chima R. Pulmonary arterial hypertension in pediatric
patients with hematopoietic stem cell transplant-associated thrombotic
microangiopathy. Biol Blood Marrow Transplant. 2013 Feb;19(2):202-7.
31. Dandoy CE, Davies SM, Hirsch R,
Chima RS, Paff Z, Cash M, et al. Abnormal echocardiography 7 days after
stem cell transplantation may be an early indicator of thrombotic
microangiopathy. Biol Blood Marrow Transplant. 2015 Jan;21(1):113-8.